https://scholars.lib.ntu.edu.tw/handle/123456789/637655
Title: | Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a double-blind, multicentre, randomised controlled, phase 3 non-inferiority trial | Authors: | Avihingsanon, Anchalee Lu, Hongzhou Leong, Chee Loon CHIEN-CHING HUNG Koenig, Ellen Kiertiburanakul, Sasisopin Lee, Man-Po Supparatpinyo, Khuanchai Zhang, Fujie Rahman, Sophia D'Antoni, Michelle L Wang, Hongyuan Hindman, Jason T Martin, Hal Baeten, Jared M Li, Taisheng |
Issue Date: | Oct-2023 | Journal Volume: | 10 | Journal Issue: | 10 | Source: | The lancet. HIV | Abstract: | For most adults with HIV-1 and hepatitis B virus (HBV) coinfection, initial recommended treatment is a tenofovir-containing antiretroviral regimen, but no randomised studies have compared tenofovir disoproxil fumarate with tenofovir alafenamide. We aimed to investigate whether bictegravir, emtricitabine, and tenofovir alafenamide is non-inferior to dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for viral suppression in individuals with HIV-1 and HBV coinfection at 48 and 96 weeks. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/637655 | ISSN: | 23523018 | DOI: | 10.1016/S2352-3018(23)00151-0 |
Appears in Collections: | 醫學系 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.